Lattanzi M, et al. - Researchers assessed the pooled long-term outcomes of three early-phase adjuvant NY-ESO-1 vaccine clinical trials in high-risk resected melanoma, relative to historical controls identified through a prospective institutional database with protocol-driven follow-up. They used the Kaplan-Meier method in order to calculate the survival times. Employment of Cox proportional hazard models was to identify significant prognostic factors and control for confounding variables. Compared with historical controls, adjuvant NY-ESO-1 vaccine immunotherapy was found to be related to longer recurrence-free and overall survival in this small retrospective cohort of resected stage III melanoma patients.